Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

NCT02564744 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma
B-cell Non-Hodgkin's Lymphoma

Interventions

DRUG: Debio 1562
DRUG: Rituximab

Sponsor

Debiopharm International SA